金河生物(002688.SZ):農業部批准公司金黴素預混劑獸藥產品增加靶動物綿羊羔羊
格隆匯10月31日丨金河生物(002688.SZ)公佈,近日,公司收到中華人民共和國農業農村部(以下簡稱"農業部")公吿第839號文件,根據《獸藥管理條例》和《獸藥註冊辦法》規定,經審查批准公司申報的金黴素預混劑獸藥產品變更註冊,發佈修訂後的説明書和標籤,自發布之日起執行,變更事項為增加靶動物綿羊羔羊。
公司本次獲得批准的金黴素預混劑獸藥產品增加靶動物綿羊羔羊是公司持續注重技術創新和研發工作取得的重要成果,將增加公司產品金黴素預混劑的適用範圍和市場空間,對提升公司市場競爭力、鞏固行業地位和可持續發展等方面具有積極的促進作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.